We are live on ! Find out more
Superstring Capital Management

Superstring Capital Management Portfolio holdings

AUM $200M Turnover 47.73%
1-Year Est. Return 216.62%
This Fund
S&P 500
This Quarter Est. Return
+16.36%
1 Year Est. Return
+216.62%
3 Year Est. Return
+1,109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
-$46.8M
Cap. Flow
-$52M
Cap. Flow %
-37.18%
Top 10 Hldgs %
57.92%
Holding
59
New
14
Increased
8
Reduced
12
Closed
24
Avg Time Held
0.5 years
Top 10 Avg Time Held
0.3 years
Top 20 Avg Time Held
0.3 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SMMT icon
1
Summit Therapeutics
SMMT
$8.4B
$16.9M 12.09%
+892,873
New +$14.4M
2026 Q1
0 quarters
IMVT icon
2
Immunovant
IMVT
$6.86B
$8.88M 6.35%
357,606
+68,929
+24% +$1.78M
2025 Q3
2 quarters
COGT icon
3
Cogent Biosciences
COGT
$4.84B
$8.67M 6.19%
225,158
-141,080
-39% -$5.21M
2024 Q4
5 quarters
SVRA icon
4
Savara
SVRA
$1.04B
$8.66M 6.19%
1,585,977
+590,624
+59% +$3.29M
2023 Q4
9 quarters
URGN icon
5
UroGen Pharma
URGN
$1.46B
$6.96M 4.98%
387,371
-330,983
-46% -$6.64M
2024 Q4
5 quarters
DFTX icon
6
Definium Therapeutics
DFTX
$3.99B
$6.64M 4.75%
351,461
-73,741
-17% -$1.25M
2025 Q4
1 quarter
VIR icon
7
Vir Biotechnology
VIR
$1.7B
$6.55M 4.68%
+730,548
New +$5.82M
2026 Q1
0 quarters
PCVX icon
8
Vaxcyte
PCVX
$9.4B
$6.42M 4.59%
+110,454
New +$6M
2026 Q1
0 quarters
CLDX icon
9
Celldex Therapeutics
CLDX
$2.2B
$5.71M 4.08%
180,048
+91,740
+104% +$2.5M
2025 Q4
1 quarter
SION icon
10
Sionna Therapeutics
SION
$139M
$5.65M 4.04%
141,024
-39,569
-22% -$1.51M
2025 Q4
1 quarter
GMAB icon
11
Genmab
GMAB
$31.4B
$5.28M 3.77%
196,709
+167,547
+575% +$5.02M
2025 Q4
1 quarter
ZLAB icon
12
Zai Lab
ZLAB
$2.76B
$5.19M 3.71%
275,818
+78,965
+40% +$1.46M
2024 Q2
7 quarters
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$136B
$4.92M 3.51%
+11,010
New +$5.13M
2026 Q1
0 quarters
IQV icon
14
IQVIA
IQV
$42.5B
$4.38M 3.13%
+25,668
New +$5.01M
2026 Q1
0 quarters
MPLT icon
15
MapLight Therapeutics
MPLT
$369M
$3.91M 2.79%
+192,139
New +$3.44M
2026 Q1
0 quarters
ARVN icon
16
Arvinas
ARVN
$447M
$3.31M 2.37%
+312,620
New +$3.87M
2026 Q1
0 quarters
ORKA icon
17
Oruka Therapeutics
ORKA
$6.53B
$3.12M 2.23%
+63,591
New +$2.21M
2026 Q1
0 quarters
UTHR icon
18
United Therapeutics
UTHR
$24.9B
$3.08M 2.2%
5,186
-4,265
-45% -$2.12M
2025 Q4
1 quarter
TVTX icon
19
Travere Therapeutics
TVTX
$4.91B
$3.05M 2.18%
102,754
+64,732
+170% +$1.94M
2025 Q1
4 quarters
TRVI icon
20
Trevi Therapeutics
TRVI
$1.93B
$3M 2.14%
251,566
+103,274
+70% +$1.16M
2025 Q4
1 quarter
ANL icon
21
Adlai Nortye Group
ANL
$610M
$2.87M 2.05%
+414,852
New +$2.77M
2026 Q1
0 quarters
CABA icon
22
Cabaletta Bio
CABA
$227M
$2.87M 2.05%
1,066,239
-1,187,311
-53% -$3.3M
2024 Q1
8 quarters
PFE icon
23
Pfizer
PFE
$160B
$2.08M 1.48%
+74,000
New +$1.97M
2026 Q1
0 quarters
AXSM icon
24
Axsome Therapeutics
AXSM
$7.15B
$1.9M 1.35%
11,217
-26,216
-70% -$4.53M
2025 Q4
1 quarter
ORIC icon
25
Oric Pharmaceuticals
ORIC
$795M
$1.46M 1.04%
115,234
-140,136
-55% -$1.59M
2024 Q3
6 quarters

Similar funds

Superstring Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Superstring Capital Management held 59 positions worth $140M, down 25% from $187M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Superstring Capital Management withdrew a net $52M in Q1 2026, closing 24 positions and reducing 12 holdings. Its most notable exit was Cidara Therapeutics, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Summit Therapeutics worth $16.9M.

  • Superstring Capital Management's largest Q1 2026 buy was Summit Therapeutics: 892,873 shares worth $16.9M.
  • Superstring Capital Management added most to Genmab in Q1 2026, an estimated $5.02M increase.
  • Superstring Capital Management's biggest Q1 2026 reduction was UroGen Pharma, cutting an estimated $6.64M.
  • Superstring Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $18.8M.
  • Superstring Capital Management's ten largest holdings make up 58% of its $140M portfolio in Q1 2026.
  • Superstring Capital Management opened 14 new positions and closed 24 in Q1 2026.
  • Superstring Capital Management's portfolio value fell 25% quarter-over-quarter to $140M.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.